Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
759
datasets available to search
ShareScore release 0.9.0
Dataset results
759 results for “disease prevention”
dataset related to article "A NOVEL BIO-INSPIRED STRATEGY TO PREVENT AMYLOIDOGENESIS AND SYNAPTIC DAMAGE IN ALZHEIMER'S DISEASE"
<p><strong>Levels of A</strong><strong>beta40, Abeta42 and aggregated Abeta</strong></p> <p><strong>results obtained from plaque count</strong></p> <p><strong>densitometric analysis of ctf and synaptic proteins</strong></p> <p><strong>levels of antibodies against Abeta42 and Abeta1-6</strong></p>
Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease
ClinicalTrials.gov study NCT03395639. IPD Sharing: YES. Countries: 14. Publications: 1.
Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors
ClinicalTrials.gov study NCT04064294. IPD Sharing: YES. Countries: 1. Publications: 3.
A Nurse-led Intervention to Extend the Veteran HIV Treatment Cascade for Cardiovascular Disease Prevention
ClinicalTrials.gov study NCT04545489. IPD Sharing: YES. Countries: 1. Publications: 2.
Raw data to "Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson's disease"
<p>Background: In vivo treatment of animals with anti-inflammatory and pro-resolving mediators (SPMs) could be counteracted by their limited in vivo bioavailability due to their unstable nature as lipids that can undergo oxidation or enzymatic degradation.</p> <p>Results: Thus, we performed a time course of RvD1 plasma levels over 36 hours after an initial intraperitonael injection of this lipid mediator at a concentration of 200 ng/animal. After a single injection the plasma concentration of RvD1 peaked at 1h (~360 pg/ml), stayed almost constant at 3h(~360 pg/ml), halved its levels after 6h (~180 pg/ml) and slowly returned close to the baseline after 36h (~30 pg/ml). These results indicate that RvD1 is rapidly distributed into the bloodstream and eliminated from the vascular compartment due to metabolism and/or diffusion into the blood–brain barrier.</p> <p>Conclusions: These findings are important to define route and timing of in vivo administration of SPMs in order to maintain sufficient levels to sustain biological activities both in the periphery and within the central nervous system.</p>
Mechanical stimulation prevents impairment of axon growth and overcompensates microtubules destabilization in cellular models of Alzheimer's disease related Tau pathology
<p>Data and metadata associated to a publication 10.3389/fmed.2025.1519628</p>
Looking in the medicine cabinet: methods for using real-world data to assess the impact of measles, mumps and rubella (MMR) and recombinant adjuvanted varicella-zoster vaccines on coronavirus disease 2019 (COVID-19) prevention and case fatality
<p>Supplementary File S1. 20210712_vx_off_target_pubdraft_S1 (Tables, Graphs and scripts associated with publication)</p> <p>Data file 1. Basic_Analysis.R (descriptive analysis script in R, for use with cleaned data files 3, 4 and 6)<br> Data file 2. Cleaning (Script demonstrating how Cerner data was cleaned upon download)<br> Data file 3. COVID_all_cleaned (CSV file with all COVID+ subjects in Cerner institutions)<br> Data file 4. COVID_mmr_data_cleaned (CSV file with COVID+ patients between 25-64 years old, including institution id, age category, gender, whether patient is in emergency department or inpatient, flu vaccine history, MMR vaccine history and mortality outcomes)<br> Data file 5. COVID_mmr_data_matched (CSV file matching MMR vaccine-exposed cases to controls based on propensity scores)<br> Data file 6. COVID_zoster_data_cleaned (CSV file with COVID+ patients above 50 years old, including institution id, age category, gender, whether patient is in emergency department or inpatient, flu vaccine history, zoster vaccine history and mortality outcomes)<br> Data file 7. COVID_zoster_data_matched (CSV file matching zoster vaccine-exposed cases to controls based on propensity scores)<br> Data file 8. General_25_64_data_cleaned (CSV file, all patients in Cerner institutions between 25 – 64 years old, including institution id, age category, gender, whether patient is in emergency department or inpatient, flu vaccine history, MMR vaccine history, SARS-CoV-2 infection and COVID-19 mortality outcomes ).<br> Data file 9. General_over50_data_cleaned (CSV file, all patients in Cerner institutions above 50 years old, including institution id, age category, gender, whether patient is in emergency department or inpatient, flu vaccine history, zoster vaccine history, SARS-CoV-2 infection and COVID-19 mortality outcomes).<br> Data file 10. Included_tenants (CSV file, institution IDs whose contributed cases comprise at least 0.5% of the aggregate sample size).<br> Data file 11. MMR_ps (R script to run for MMR-related files analysis)<br> Data file 12. Zoster_ps (R script to run for zoster-related files analysis)</p>
Phase II Study of Heart Polypill Safety and Efficacy in Primary Prevention of Cardiovascular Disease
ClinicalTrials.gov study NCT00603590. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery
ClinicalTrials.gov study NCT01989572. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remis
ClinicalTrials.gov study NCT00382109. IPD Sharing: Not stated. Countries: 3. Publications: 2.
Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease
ClinicalTrials.gov study NCT04405999. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)
ClinicalTrials.gov study NCT00500682. IPD Sharing: Not stated. Countries: 12. Publications: 3.
Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7
ClinicalTrials.gov study NCT02663622. IPD Sharing: YES. Countries: 1. Publications: 4.
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
ClinicalTrials.gov study NCT01776424. IPD Sharing: NO. Countries: 33. Publications: 66.
Efficacy of Probiotics (LiveSpo Navax) in Preventing Respiratory Diseases in Children
ClinicalTrials.gov study NCT06148194. IPD Sharing: YES. Countries: 1. Publications: 9.
A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention
ClinicalTrials.gov study NCT03643705. IPD Sharing: YES. Countries: 1. Publications: 4.
A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients
ClinicalTrials.gov study NCT00739648. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Prevention of Cardiovascular Disease With Med or Veg Diets
ClinicalTrials.gov study NCT02641834. IPD Sharing: YES. Countries: 1. Publications: 4.
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
ClinicalTrials.gov study NCT01427881. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease
ClinicalTrials.gov study NCT01684722. IPD Sharing: Not stated. Countries: 1. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.